Small-cap biotech companies (valued at £250m-£2bn) can experience significant movements when clinical developments or partnerships influence sentiment. Below are five of the leading small-cap biotech stocks by market capitalisation, calculated by multiplying each share price by the number of ordinary shares in issue (fully diluted) as of 30 April 2026.
Our rankings show the leading small-cap biotech shares for CFD traders worldwide as of 30 April 2026. Each company’s market capitalisation is presented in US dollars (USD), together with its latest share price and main listing location.
| Rank | Company | Market cap (USD) | Share price (USD) | Country |
|---|---|---|---|---|
| 1 | Tyra Biosciences | $2bn | $33.78 | USA |
| 2 | Nippon Shinyaku | $2bn | $29.82 | Japan |
| 3 | Ocular Therapeutix | $2bn | $9.21 | USA |
| 4 | Aurinia Pharmaceuticals | $2bn | $15.28 | Canada |
| 5 | Trevi Therapeutics | $2bn | $13.82 | USA |
| 6 | Pharvaris | $2bn | $29.83 | Netherlands |
| 7 | HBM Healthcare Investments | $1.9bn | $293.31 | Switzerland |
| 8 | Pharma Mar | $1.9bn | $111.10 | Spain |
| 9 | Stoke Therapeutics | $1.9bn | $32.42 | USA |
| 10 | Capricor Therapeutics | $1.9bn | $32.46 | USA |
| 11 | Galapagos NV | $1.9bn | $27.86 | Belgium |
| 12 | Tecan | $1.8bn | $146.02 | Switzerland |
| 13 | GeneDx Holdings | $1.8bn | $62.90 | USA |
| 14 | Granules India | $1.8bn | $7.38 | India |
| 15 | Inhibrx Biosciences | $1.8bn | $124.82 | USA |
The information on this page is based on public disclosures and market data. It is provided for informational purposes only and does not constitute investment advice. Figures are believed to be accurate as of the stated date but may change without notice.
Small-cap biotech valuations tend to depend more on pipeline progress than current revenue, as many companies at this stage have little or no product income. That makes the sector especially sensitive to clinical trial results, regulatory decisions and other binary events that can quickly reshape views of a company's commercial potential. Wider sector conditions also matter. RBC Capital Markets noted that several indicators were supportive as 2026 began, including strong drug launches, improving investor sentiment and rising capital inflows (RBC Capital Markets, 27 January 2026). Forecasts also suggest the global biotech market could expand at a compound annual growth rate (CAGR) of 12.5% until 2034, potentially reaching $5,036.46bn (GlobeNewswire, 10 April 2025). That broader backdrop may support interest in smaller firms, particularly those focused on niche therapies or faster regulatory pathways. Even so, valuations can change quickly when clinical, funding or commercial expectations shift.
Interest rates and macro conditions can have a pronounced effect on small-cap biotech stocks because many early-stage companies rely on external funding to support research and development. When rates are high, capital becomes more expensive and investor appetite for higher-risk, longer-duration assets often weakens – capital raised by dedicated biotech VC funds shrank from around $30.8bn in 2021 to $11.7bn in 2024, in part as higher interest rates made it harder to raise new funds (Alacrita, accessed 30 April 2026). Lower rates, by contrast, can make funding easier to access and development plans easier to sustain. The Federal Reserve's rate cuts, beginning in September 2024, sparked optimism in the sector, with TD Cowen analysts noting that small-cap biotech firms were likely to experience the most immediate benefits through improved access to capital (Clarita Rx, 24 February 2026). As 2026 began, a steadier rate backdrop and late-2025 Federal Reserve easing were associated with a broader sector recovery, with venture funding in biotech growing 70.9% year-on-year in Q3 2025 (Yahoo Finance, 23 October 2025). Still, easier monetary conditions do not remove funding risk. Smaller biotech companies can remain highly sensitive to changes in capital markets, sentiment and the wider economic outlook.
The FDA's regulatory approach is another key factor in small-cap biotech valuations because it shapes how quickly companies can move pipeline assets towards commercialisation. In 2025, the FDA approved 46 novel drugs, broadly in line with the 10-year average, with 43% classified as first-in-class treatments with mechanisms of action different from any existing therapy (FDA, 23 April 2026). In February 2026, the FDA announced a significant shift in default approval standards, moving to require only a single pivotal trial for drug approvals instead of two – a change that could substantially reduce development costs and timelines, particularly for smaller firms (Clinical Trials Arena, 20 February 2026). Separately, the FDA's proposed budget for 2026 includes a new expedited clinical trial notification pathway specifically noted as important for smaller biotechnology firms that face greater barriers to entry under the current framework (RAPS, 7 April 2026). These developments may improve the development outlook for some companies, but rejections, additional data requests and review delays can still create uncertainty – particularly for companies with only one or two key pipeline assets – meaning regulatory updates often have a direct and swift effect on share prices.
Small-cap biotech stocks have a market capitalisation typically between £250m and £2bn. Firms below this range are often referred to as ‘micro caps’. They focus on developing new therapies, which can make them higher risk and subject to significant price movements if trials or partnerships influence sentiment.
To trade small-cap biotech shares via contracts for difference (CFDs), you’ll need to open and verify an account with a regulated provider (such as one authorised by the FCA or ASIC). CFDs are traded on margin, and leverage can amplify both profits and losses. After depositing funds, select the biotech share CFD you want to trade and place an order through your platform’s order ticket – choosing either a market or limit order – to take a long or short position. Risk-management tools such as stop-loss and take-profit orders can help manage exposure before trading live. Standard stop-loss orders are not guaranteed. Guaranteed stop-loss orders (GSLOs) incur a fee if activated.
Biotech stocks can be volatile around clinical trial results, regulatory decisions and partnership announcements. Unexpected trial outcomes or funding constraints may also cause large price movements. CFDs are leveraged instruments, meaning both gains and losses are magnified. Traders may also face margin calls or overnight financing charges. It’s important to apply risk management measures, maintain appropriate position sizes and avoid excessive leverage.
Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.
Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.
Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.
I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!
I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️
I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.
Love the TV integration. Makes traders life smooth and comfortable.
I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!
I’d been paper trading for 2yrs now, went live and this platform is easy for beginners to understand and navigate all important tools to execute all that I learned. Earning now!
This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one
User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.
Capital is really great to be used on start, also beginner friendly broker! Great costumer support and it is quick!
Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.
Why choose Capital.com? Our numbers speak for themselves
Capital.com Group
Ratings and Reviews
Ratings and Reviews